Another large longitudinal study by Chen et al. on 399,810 patients with T2DM demonstrated that SGLT2 inhibitors were linked to significantly reduce risk of all-cause mortality and new-onset arrhythmias compared to participants that were not on any SGLT2 inhibitors [25]. Here, SLC5A2 is linked to type 2 diabetes mellitus.